nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—CYP1A2—chronic obstructive pulmonary disease	0.504	1	CbGaD
Leflunomide—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0549	0.27	CbGbCtD
Leflunomide—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0549	0.27	CbGbCtD
Leflunomide—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0518	0.255	CbGbCtD
Leflunomide—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0416	0.205	CbGbCtD
Leflunomide—PTK2B—respiratory system—chronic obstructive pulmonary disease	0.00257	0.141	CbGeAlD
Leflunomide—PTK2B—connective tissue—chronic obstructive pulmonary disease	0.00226	0.124	CbGeAlD
Leflunomide—DHODH—lung—chronic obstructive pulmonary disease	0.00215	0.118	CbGeAlD
Leflunomide—CYP1A2—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00215	0.0364	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.00214	0.0362	CbGpPWpGaD
Leflunomide—PTK2B—smooth muscle tissue—chronic obstructive pulmonary disease	0.00207	0.114	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—CYP1A2—chronic obstructive pulmonary disease	0.0018	0.0304	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—CYP1A2—chronic obstructive pulmonary disease	0.0018	0.0304	CbGpPWpGaD
Leflunomide—AHR—bronchus—chronic obstructive pulmonary disease	0.00174	0.0956	CbGeAlD
Leflunomide—AHR—smooth muscle tissue—chronic obstructive pulmonary disease	0.0017	0.0936	CbGeAlD
Leflunomide—AHR—trachea—chronic obstructive pulmonary disease	0.00156	0.0859	CbGeAlD
Leflunomide—PTK2B—lung—chronic obstructive pulmonary disease	0.00136	0.075	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.00131	0.0221	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	0.00131	0.0221	CbGpPWpGaD
Leflunomide—AHR—lung—chronic obstructive pulmonary disease	0.00112	0.0617	CbGeAlD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—GCLC—chronic obstructive pulmonary disease	0.00105	0.0177	CbGpPWpGaD
Leflunomide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.00094	0.0159	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.000872	0.0147	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—PLAU—chronic obstructive pulmonary disease	0.000866	0.0146	CbGpPWpGaD
Leflunomide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.000855	0.0144	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—KL—chronic obstructive pulmonary disease	0.000817	0.0138	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—MMP14—chronic obstructive pulmonary disease	0.000809	0.0137	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—ADIPOQ—chronic obstructive pulmonary disease	0.000796	0.0134	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—PLAUR—chronic obstructive pulmonary disease	0.000792	0.0134	CbGpPWpGaD
Leflunomide—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000788	0.0434	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	0.000723	0.0122	CbGpPWpGaD
Leflunomide—CYP1A2—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000685	0.0116	CbGpPWpGaD
Leflunomide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000683	0.0115	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—IL17A—chronic obstructive pulmonary disease	0.000651	0.011	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—ERBB3—chronic obstructive pulmonary disease	0.000621	0.0105	CbGpPWpGaD
Leflunomide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000621	0.0105	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	0.000612	0.0103	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—SLC6A4—chronic obstructive pulmonary disease	0.000611	0.0103	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—EDN1—chronic obstructive pulmonary disease	0.000595	0.0101	CbGpPWpGaD
Leflunomide—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000583	0.00986	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—APIP—chronic obstructive pulmonary disease	0.000578	0.00976	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	0.000562	0.0095	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000561	0.00948	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.000559	0.00945	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—PLAU—chronic obstructive pulmonary disease	0.000556	0.00939	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	0.000551	0.00931	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	0.000551	0.00931	CbGpPWpGaD
Leflunomide—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000531	0.00897	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	0.000525	0.00887	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	0.000525	0.00887	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—MMP9—chronic obstructive pulmonary disease	0.000513	0.00867	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—MMP1—chronic obstructive pulmonary disease	0.0005	0.00845	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—LEP—chronic obstructive pulmonary disease	0.000494	0.00835	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—MMP1—chronic obstructive pulmonary disease	0.000488	0.00825	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MMP1—chronic obstructive pulmonary disease	0.000453	0.00765	CbGpPWpGaD
Leflunomide—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000452	0.00763	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—CD8A—chronic obstructive pulmonary disease	0.000437	0.00739	CbGpPWpGaD
Leflunomide—ABCG2—lung—chronic obstructive pulmonary disease	0.000435	0.0239	CbGeAlD
Leflunomide—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000434	0.00734	CbGpPWpGaD
Leflunomide—CYP1A2—lung—chronic obstructive pulmonary disease	0.000419	0.023	CbGeAlD
Leflunomide—ABCG2—Iron uptake and transport—HMOX1—chronic obstructive pulmonary disease	0.000399	0.00673	CbGpPWpGaD
Leflunomide—CYP1A2—Estrogen Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000396	0.00668	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—SERPINE1—chronic obstructive pulmonary disease	0.000388	0.00655	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000383	0.00646	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GC—chronic obstructive pulmonary disease	0.000372	0.00629	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—SERPINE1—chronic obstructive pulmonary disease	0.000371	0.00626	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	0.000349	0.00589	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000346	0.00585	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—chronic obstructive pulmonary disease	0.000341	0.00577	CbGpPWpGaD
Leflunomide—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000335	0.00566	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—MMP9—chronic obstructive pulmonary disease	0.000329	0.00556	CbGpPWpGaD
Leflunomide—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000328	0.00554	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	0.000325	0.00549	CbGpPWpGaD
Leflunomide—CYP1A2—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000322	0.00544	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—CXCL8—chronic obstructive pulmonary disease	0.000318	0.00537	CbGpPWpGaD
Leflunomide—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000315	0.00533	CbGpPWpGaD
Leflunomide—CYP1A2—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000305	0.00515	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000295	0.00499	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.000289	0.00489	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—MMP9—chronic obstructive pulmonary disease	0.000287	0.00486	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000283	0.00478	CbGpPWpGaD
Leflunomide—CYP1A2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00028	0.00474	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	0.000274	0.00462	CbGpPWpGaD
Leflunomide—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00027	0.00455	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.000267	0.00451	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—VEGFA—chronic obstructive pulmonary disease	0.000261	0.00442	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—chronic obstructive pulmonary disease	0.000257	0.00435	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—VEGFA—chronic obstructive pulmonary disease	0.000255	0.00431	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—chronic obstructive pulmonary disease	0.000246	0.00415	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—TGFB1—chronic obstructive pulmonary disease	0.000245	0.00414	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000245	0.00413	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—NOS3—chronic obstructive pulmonary disease	0.000237	0.00401	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	0.000237	0.004	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000236	0.00398	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—EGFR—chronic obstructive pulmonary disease	0.000232	0.00392	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—IL1B—chronic obstructive pulmonary disease	0.000232	0.00392	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—MMP9—chronic obstructive pulmonary disease	0.000231	0.00391	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—TNF—chronic obstructive pulmonary disease	0.000229	0.00386	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—IL6—chronic obstructive pulmonary disease	0.000229	0.00386	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—NOS3—chronic obstructive pulmonary disease	0.000224	0.00379	CbGpPWpGaD
Leflunomide—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000224	0.00104	CcSEcCtD
Leflunomide—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000224	0.00104	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000223	0.00104	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000223	0.00104	CcSEcCtD
Leflunomide—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000222	0.00375	CbGpPWpGaD
Leflunomide—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000222	0.00103	CcSEcCtD
Leflunomide—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000222	0.00103	CcSEcCtD
Leflunomide—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.00102	CcSEcCtD
Leflunomide—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.00022	0.00102	CcSEcCtD
Leflunomide—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.00022	0.00102	CcSEcCtD
Leflunomide—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00102	CcSEcCtD
Leflunomide—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00102	CcSEcCtD
Leflunomide—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000219	0.00102	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000219	0.00102	CcSEcCtD
Leflunomide—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000218	0.00102	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000218	0.00369	CbGpPWpGaD
Leflunomide—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000218	0.00101	CcSEcCtD
Leflunomide—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000218	0.00101	CcSEcCtD
Leflunomide—Oesophagitis—Prednisone—chronic obstructive pulmonary disease	0.000217	0.00101	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000217	0.00366	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	0.000217	0.00366	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000216	0.001	CcSEcCtD
Leflunomide—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.001	CcSEcCtD
Leflunomide—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.001	CcSEcCtD
Leflunomide—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.000215	0.000999	CcSEcCtD
Leflunomide—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000214	0.000995	CcSEcCtD
Leflunomide—Infection—Formoterol—chronic obstructive pulmonary disease	0.000214	0.000995	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—EGFR—chronic obstructive pulmonary disease	0.000213	0.0036	CbGpPWpGaD
Leflunomide—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000212	0.000987	CcSEcCtD
Leflunomide—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000212	0.000987	CcSEcCtD
Leflunomide—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000212	0.000987	CcSEcCtD
Leflunomide—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000212	0.000986	CcSEcCtD
Leflunomide—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000212	0.000983	CcSEcCtD
Leflunomide—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000211	0.000983	CcSEcCtD
Leflunomide—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000211	0.000983	CcSEcCtD
Leflunomide—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000211	0.000981	CcSEcCtD
Leflunomide—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000211	0.000981	CcSEcCtD
Leflunomide—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00021	0.000978	CcSEcCtD
Leflunomide—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00021	0.000978	CcSEcCtD
Leflunomide—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00021	0.000975	CcSEcCtD
Leflunomide—Infection—Montelukast—chronic obstructive pulmonary disease	0.00021	0.000975	CcSEcCtD
Leflunomide—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000209	0.000973	CcSEcCtD
Leflunomide—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000209	0.000973	CcSEcCtD
Leflunomide—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000209	0.00097	CcSEcCtD
Leflunomide—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000208	0.00352	CbGpPWpGaD
Leflunomide—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.000965	CcSEcCtD
Leflunomide—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000207	0.000962	CcSEcCtD
Leflunomide—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000207	0.000961	CcSEcCtD
Leflunomide—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000206	0.000959	CcSEcCtD
Leflunomide—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000205	0.000953	CcSEcCtD
Leflunomide—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.000946	CcSEcCtD
Leflunomide—DHODH—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000203	0.00344	CbGpPWpGaD
Leflunomide—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000202	0.00094	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	0.000202	0.00341	CbGpPWpGaD
Leflunomide—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000201	0.000936	CcSEcCtD
Leflunomide—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000201	0.000936	CcSEcCtD
Leflunomide—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000201	0.000936	CcSEcCtD
Leflunomide—DHODH—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000201	0.0034	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL1B—chronic obstructive pulmonary disease	0.000201	0.00339	CbGpPWpGaD
Leflunomide—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.0002	0.000931	CcSEcCtD
Leflunomide—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.0002	0.000929	CcSEcCtD
Leflunomide—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.000928	CcSEcCtD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	0.000199	0.00336	CbGpPWpGaD
Leflunomide—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000199	0.000923	CcSEcCtD
Leflunomide—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000198	0.000922	CcSEcCtD
Leflunomide—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000198	0.000919	CcSEcCtD
Leflunomide—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000197	0.000915	CcSEcCtD
Leflunomide—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.000915	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000196	0.000913	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000196	0.000913	CcSEcCtD
Leflunomide—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000195	0.000906	CcSEcCtD
Leflunomide—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000195	0.000906	CcSEcCtD
Leflunomide—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000194	0.000902	CcSEcCtD
Leflunomide—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000194	0.000901	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—chronic obstructive pulmonary disease	0.000193	0.00325	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000192	0.000894	CcSEcCtD
Leflunomide—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000192	0.000893	CcSEcCtD
Leflunomide—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000192	0.000893	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000192	0.00324	CbGpPWpGaD
Leflunomide—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000191	0.000888	CcSEcCtD
Leflunomide—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.000884	CcSEcCtD
Leflunomide—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.000882	CcSEcCtD
Leflunomide—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.00019	0.000882	CcSEcCtD
Leflunomide—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.00019	0.000881	CcSEcCtD
Leflunomide—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000189	0.000878	CcSEcCtD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000187	0.00317	CbGpPWpGaD
Leflunomide—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000187	0.000871	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.000865	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000186	0.000865	CcSEcCtD
Leflunomide—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000186	0.000864	CcSEcCtD
Leflunomide—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000186	0.000864	CcSEcCtD
Leflunomide—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.000864	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.000862	CcSEcCtD
Leflunomide—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000185	0.00313	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—IL6—chronic obstructive pulmonary disease	0.000184	0.00312	CbGpPWpGaD
Leflunomide—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000184	0.000857	CcSEcCtD
Leflunomide—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000184	0.000857	CcSEcCtD
Leflunomide—Pain—Formoterol—chronic obstructive pulmonary disease	0.000184	0.000857	CcSEcCtD
Leflunomide—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000184	0.000857	CcSEcCtD
Leflunomide—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000184	0.000856	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000184	0.0031	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000183	0.0031	CbGpPWpGaD
Leflunomide—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.000849	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000182	0.000847	CcSEcCtD
Leflunomide—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000182	0.000846	CcSEcCtD
Leflunomide—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.000843	CcSEcCtD
Leflunomide—Pain—Montelukast—chronic obstructive pulmonary disease	0.000181	0.000839	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—TGFB1—chronic obstructive pulmonary disease	0.00018	0.00305	CbGpPWpGaD
Leflunomide—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00018	0.000837	CcSEcCtD
Leflunomide—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000179	0.000834	CcSEcCtD
Leflunomide—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.000833	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—chronic obstructive pulmonary disease	0.000179	0.00302	CbGpPWpGaD
Leflunomide—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000179	0.00083	CcSEcCtD
Leflunomide—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000178	0.000829	CcSEcCtD
Leflunomide—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000178	0.000827	CcSEcCtD
Leflunomide—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000178	0.000826	CcSEcCtD
Leflunomide—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.000826	CcSEcCtD
Leflunomide—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000177	0.000825	CcSEcCtD
Leflunomide—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.000822	CcSEcCtD
Leflunomide—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000177	0.000821	CcSEcCtD
Leflunomide—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000176	0.000819	CcSEcCtD
Leflunomide—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000176	0.000819	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000176	0.000817	CcSEcCtD
Leflunomide—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.000816	CcSEcCtD
Leflunomide—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000174	0.000809	CcSEcCtD
Leflunomide—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000174	0.000809	CcSEcCtD
Leflunomide—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000173	0.000802	CcSEcCtD
Leflunomide—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000173	0.000802	CcSEcCtD
Leflunomide—PTK2B—Immune System—RAPGEF3—chronic obstructive pulmonary disease	0.000172	0.00291	CbGpPWpGaD
Leflunomide—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.000796	CcSEcCtD
Leflunomide—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000171	0.000796	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—VEGFA—chronic obstructive pulmonary disease	0.000171	0.00289	CbGpPWpGaD
Leflunomide—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00017	0.000792	CcSEcCtD
Leflunomide—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.000792	CcSEcCtD
Leflunomide—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.00017	0.000792	CcSEcCtD
Leflunomide—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.000792	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—NOS3—chronic obstructive pulmonary disease	0.00017	0.00288	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.00017	0.00288	CbGpPWpGaD
Leflunomide—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00017	0.000789	CcSEcCtD
Leflunomide—DHODH—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000169	0.00285	CbGpPWpGaD
Leflunomide—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000168	0.000783	CcSEcCtD
Leflunomide—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000168	0.000782	CcSEcCtD
Leflunomide—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000168	0.000782	CcSEcCtD
Leflunomide—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000168	0.00078	CcSEcCtD
Leflunomide—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.00078	CcSEcCtD
Leflunomide—PTK2B—Immune System—LY96—chronic obstructive pulmonary disease	0.000167	0.00283	CbGpPWpGaD
Leflunomide—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000167	0.000778	CcSEcCtD
Leflunomide—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000167	0.000776	CcSEcCtD
Leflunomide—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000167	0.000776	CcSEcCtD
Leflunomide—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.000774	CcSEcCtD
Leflunomide—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.000768	CcSEcCtD
Leflunomide—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.000764	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000164	0.00277	CbGpPWpGaD
Leflunomide—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.000752	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—VEGFA—chronic obstructive pulmonary disease	0.000161	0.00273	CbGpPWpGaD
Leflunomide—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.000748	CcSEcCtD
Leflunomide—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.000748	CcSEcCtD
Leflunomide—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000159	0.000738	CcSEcCtD
Leflunomide—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000159	0.000738	CcSEcCtD
Leflunomide—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000159	0.000737	CcSEcCtD
Leflunomide—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000158	0.000735	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000158	0.00266	CbGpPWpGaD
Leflunomide—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000157	0.00073	CcSEcCtD
Leflunomide—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000156	0.000723	CcSEcCtD
Leflunomide—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000155	0.000719	CcSEcCtD
Leflunomide—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000155	0.000719	CcSEcCtD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—chronic obstructive pulmonary disease	0.000154	0.0026	CbGpPWpGaD
Leflunomide—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000153	0.000709	CcSEcCtD
Leflunomide—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000153	0.000709	CcSEcCtD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000152	0.00257	CbGpPWpGaD
Leflunomide—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000151	0.000704	CcSEcCtD
Leflunomide—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00015	0.000697	CcSEcCtD
Leflunomide—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000149	0.000694	CcSEcCtD
Leflunomide—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000147	0.000686	CcSEcCtD
Leflunomide—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000147	0.000686	CcSEcCtD
Leflunomide—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.000682	CcSEcCtD
Leflunomide—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000146	0.00068	CcSEcCtD
Leflunomide—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000146	0.000679	CcSEcCtD
Leflunomide—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000145	0.000675	CcSEcCtD
Leflunomide—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000144	0.000671	CcSEcCtD
Leflunomide—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.000669	CcSEcCtD
Leflunomide—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000144	0.00243	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	0.000144	0.00243	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000144	0.00243	CbGpPWpGaD
Leflunomide—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000143	0.000663	CcSEcCtD
Leflunomide—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000143	0.000663	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	0.000142	0.0024	CbGpPWpGaD
Leflunomide—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.000142	0.0024	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000141	0.00238	CbGpPWpGaD
Leflunomide—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	0.00014	0.00237	CbGpPWpGaD
Leflunomide—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00014	0.000649	CcSEcCtD
Leflunomide—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000648	CcSEcCtD
Leflunomide—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000139	0.000647	CcSEcCtD
Leflunomide—DHODH—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000139	0.00235	CbGpPWpGaD
Leflunomide—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.000637	CcSEcCtD
Leflunomide—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000137	0.000637	CcSEcCtD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000136	0.0023	CbGpPWpGaD
Leflunomide—Rash—Formoterol—chronic obstructive pulmonary disease	0.000136	0.000632	CcSEcCtD
Leflunomide—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000136	0.000632	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—IL6—chronic obstructive pulmonary disease	0.000136	0.0023	CbGpPWpGaD
Leflunomide—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000136	0.000631	CcSEcCtD
Leflunomide—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000136	0.000631	CcSEcCtD
Leflunomide—Headache—Formoterol—chronic obstructive pulmonary disease	0.000135	0.000628	CcSEcCtD
Leflunomide—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000135	0.000628	CcSEcCtD
Leflunomide—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000627	CcSEcCtD
Leflunomide—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000135	0.000627	CcSEcCtD
Leflunomide—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000135	0.00228	CbGpPWpGaD
Leflunomide—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000135	0.000626	CcSEcCtD
Leflunomide—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000625	CcSEcCtD
Leflunomide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000134	0.00227	CbGpPWpGaD
Leflunomide—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000134	0.000624	CcSEcCtD
Leflunomide—Rash—Montelukast—chronic obstructive pulmonary disease	0.000133	0.000619	CcSEcCtD
Leflunomide—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000133	0.000618	CcSEcCtD
Leflunomide—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.000617	CcSEcCtD
Leflunomide—Headache—Montelukast—chronic obstructive pulmonary disease	0.000132	0.000615	CcSEcCtD
Leflunomide—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000131	0.000607	CcSEcCtD
Leflunomide—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.00013	0.000606	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	0.00013	0.0022	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GSTM1—chronic obstructive pulmonary disease	0.00013	0.00219	CbGpPWpGaD
Leflunomide—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000129	0.000602	CcSEcCtD
Leflunomide—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000129	0.0006	CcSEcCtD
Leflunomide—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000129	0.000597	CcSEcCtD
Leflunomide—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000128	0.000596	CcSEcCtD
Leflunomide—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000128	0.000596	CcSEcCtD
Leflunomide—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.000595	CcSEcCtD
Leflunomide—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000128	0.000595	CcSEcCtD
Leflunomide—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000128	0.000593	CcSEcCtD
Leflunomide—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000125	0.000583	CcSEcCtD
Leflunomide—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.000574	CcSEcCtD
Leflunomide—DHODH—Metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000123	0.00207	CbGpPWpGaD
Leflunomide—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.000562	CcSEcCtD
Leflunomide—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.00012	0.000559	CcSEcCtD
Leflunomide—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000558	CcSEcCtD
Leflunomide—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000555	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—IL6—chronic obstructive pulmonary disease	0.000118	0.002	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL6—chronic obstructive pulmonary disease	0.000117	0.00198	CbGpPWpGaD
Leflunomide—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000545	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	0.000117	0.00198	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.000543	CcSEcCtD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000116	0.00197	CbGpPWpGaD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000115	0.00194	CbGpPWpGaD
Leflunomide—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000114	0.00053	CcSEcCtD
Leflunomide—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000113	0.000525	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—IL6—chronic obstructive pulmonary disease	0.000112	0.00189	CbGpPWpGaD
Leflunomide—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000519	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000111	0.00188	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—EGFR—chronic obstructive pulmonary disease	0.00011	0.00187	CbGpPWpGaD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00011	0.00187	CbGpPWpGaD
Leflunomide—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000501	CcSEcCtD
Leflunomide—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000496	CcSEcCtD
Leflunomide—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000491	CcSEcCtD
Leflunomide—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000106	0.00049	CcSEcCtD
Leflunomide—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000105	0.000487	CcSEcCtD
Leflunomide—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000486	CcSEcCtD
Leflunomide—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000483	CcSEcCtD
Leflunomide—Pain—Prednisolone—chronic obstructive pulmonary disease	9.98e-05	0.000464	CcSEcCtD
Leflunomide—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	9.84e-05	0.00166	CbGpPWpGaD
Leflunomide—Vision blurred—Prednisone—chronic obstructive pulmonary disease	9.8e-05	0.000455	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	9.71e-05	0.00164	CbGpPWpGaD
Leflunomide—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	9.64e-05	0.000448	CcSEcCtD
Leflunomide—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	9.62e-05	0.000447	CcSEcCtD
Leflunomide—Anaemia—Prednisone—chronic obstructive pulmonary disease	9.61e-05	0.000447	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	9.6e-05	0.00162	CbGpPWpGaD
Leflunomide—Angioedema—Prednisone—chronic obstructive pulmonary disease	9.5e-05	0.000441	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	9.44e-05	0.00159	CbGpPWpGaD
Leflunomide—Malaise—Prednisone—chronic obstructive pulmonary disease	9.37e-05	0.000436	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL1B—chronic obstructive pulmonary disease	9.36e-05	0.00158	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APIP—chronic obstructive pulmonary disease	9.34e-05	0.00158	CbGpPWpGaD
Leflunomide—Vertigo—Prednisone—chronic obstructive pulmonary disease	9.34e-05	0.000434	CcSEcCtD
Leflunomide—Urticaria—Prednisolone—chronic obstructive pulmonary disease	9.27e-05	0.000431	CcSEcCtD
Leflunomide—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	9.04e-05	0.00153	CbGpPWpGaD
Leflunomide—Hypertension—Prednisone—chronic obstructive pulmonary disease	8.97e-05	0.000417	CcSEcCtD
Leflunomide—Arthralgia—Prednisone—chronic obstructive pulmonary disease	8.85e-05	0.000411	CcSEcCtD
Leflunomide—Myalgia—Prednisone—chronic obstructive pulmonary disease	8.85e-05	0.000411	CcSEcCtD
Leflunomide—Anxiety—Prednisone—chronic obstructive pulmonary disease	8.82e-05	0.00041	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	8.79e-05	0.000408	CcSEcCtD
Leflunomide—Discomfort—Prednisone—chronic obstructive pulmonary disease	8.74e-05	0.000406	CcSEcCtD
Leflunomide—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	8.6e-05	0.0004	CcSEcCtD
Leflunomide—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	8.48e-05	0.000394	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	8.44e-05	0.00143	CbGpPWpGaD
Leflunomide—Infection—Prednisone—chronic obstructive pulmonary disease	8.43e-05	0.000392	CcSEcCtD
Leflunomide—DHODH—Metabolism—ALB—chronic obstructive pulmonary disease	8.35e-05	0.00141	CbGpPWpGaD
Leflunomide—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	8.32e-05	0.000387	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	8.3e-05	0.0014	CbGpPWpGaD
Leflunomide—Tachycardia—Prednisone—chronic obstructive pulmonary disease	8.28e-05	0.000385	CcSEcCtD
Leflunomide—Skin disorder—Prednisone—chronic obstructive pulmonary disease	8.24e-05	0.000383	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	8.21e-05	0.00139	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	8.2e-05	0.000381	CcSEcCtD
Leflunomide—Anorexia—Prednisone—chronic obstructive pulmonary disease	8.09e-05	0.000376	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	8.07e-05	0.00136	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—NOS3—chronic obstructive pulmonary disease	7.98e-05	0.00135	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	7.97e-05	0.00135	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	7.96e-05	0.00135	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	7.73e-05	0.000359	CcSEcCtD
Leflunomide—Dizziness—Prednisolone—chronic obstructive pulmonary disease	7.72e-05	0.000359	CcSEcCtD
Leflunomide—Insomnia—Prednisone—chronic obstructive pulmonary disease	7.67e-05	0.000357	CcSEcCtD
Leflunomide—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	7.62e-05	0.000354	CcSEcCtD
Leflunomide—PTK2B—Immune System—TLR2—chronic obstructive pulmonary disease	7.6e-05	0.00128	CbGpPWpGaD
Leflunomide—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	7.47e-05	0.000347	CcSEcCtD
Leflunomide—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	7.37e-05	0.000343	CcSEcCtD
Leflunomide—Rash—Prednisolone—chronic obstructive pulmonary disease	7.36e-05	0.000342	CcSEcCtD
Leflunomide—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	7.35e-05	0.000342	CcSEcCtD
Leflunomide—Fatigue—Prednisone—chronic obstructive pulmonary disease	7.31e-05	0.00034	CcSEcCtD
Leflunomide—Headache—Prednisolone—chronic obstructive pulmonary disease	7.31e-05	0.00034	CcSEcCtD
Leflunomide—Constipation—Prednisone—chronic obstructive pulmonary disease	7.25e-05	0.000337	CcSEcCtD
Leflunomide—PTK2B—Immune System—KL—chronic obstructive pulmonary disease	7.15e-05	0.00121	CbGpPWpGaD
Leflunomide—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	6.99e-05	0.000325	CcSEcCtD
Leflunomide—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	6.94e-05	0.000322	CcSEcCtD
Leflunomide—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.93e-05	0.000322	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	6.83e-05	0.00115	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	6.8e-05	0.00115	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	6.74e-05	0.00114	CbGpPWpGaD
Leflunomide—Urticaria—Prednisone—chronic obstructive pulmonary disease	6.74e-05	0.000313	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.73e-05	0.00114	CbGpPWpGaD
Leflunomide—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	6.71e-05	0.000312	CcSEcCtD
Leflunomide—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	6.71e-05	0.000312	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	6.64e-05	0.00112	CbGpPWpGaD
Leflunomide—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	6.25e-05	0.00029	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	6.19e-05	0.00105	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.19e-05	0.00105	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.19e-05	0.00105	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.1e-05	0.00103	CbGpPWpGaD
Leflunomide—Asthenia—Prednisone—chronic obstructive pulmonary disease	6.09e-05	0.000283	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	6.07e-05	0.00103	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	6.07e-05	0.00103	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GC—chronic obstructive pulmonary disease	6.02e-05	0.00102	CbGpPWpGaD
Leflunomide—Pruritus—Prednisone—chronic obstructive pulmonary disease	6e-05	0.000279	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.87e-05	0.000991	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.84e-05	0.000986	CbGpPWpGaD
Leflunomide—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.8e-05	0.00027	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.79e-05	0.000977	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	5.78e-05	0.000977	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	5.78e-05	0.000977	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD8A—chronic obstructive pulmonary disease	5.76e-05	0.000974	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.75e-05	0.000972	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.68e-05	0.000959	CbGpPWpGaD
Leflunomide—Dizziness—Prednisone—chronic obstructive pulmonary disease	5.61e-05	0.000261	CcSEcCtD
Leflunomide—ABCG2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.6e-05	0.000946	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL6—chronic obstructive pulmonary disease	5.48e-05	0.000926	CbGpPWpGaD
Leflunomide—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.39e-05	0.000251	CcSEcCtD
Leflunomide—PTK2B—Immune System—ERBB3—chronic obstructive pulmonary disease	5.36e-05	0.000905	CbGpPWpGaD
Leflunomide—Rash—Prednisone—chronic obstructive pulmonary disease	5.35e-05	0.000249	CcSEcCtD
Leflunomide—Dermatitis—Prednisone—chronic obstructive pulmonary disease	5.34e-05	0.000248	CcSEcCtD
Leflunomide—Headache—Prednisone—chronic obstructive pulmonary disease	5.31e-05	0.000247	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.29e-05	0.000893	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.22e-05	0.000881	CbGpPWpGaD
Leflunomide—Nausea—Prednisone—chronic obstructive pulmonary disease	5.04e-05	0.000234	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.01e-05	0.000847	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	4.97e-05	0.00084	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.94e-05	0.000835	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CRP—chronic obstructive pulmonary disease	4.9e-05	0.000828	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	4.8e-05	0.000811	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	4.72e-05	0.000797	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR4—chronic obstructive pulmonary disease	4.7e-05	0.000794	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KL—chronic obstructive pulmonary disease	4.62e-05	0.000781	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.27e-05	0.000721	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	4.03e-05	0.000681	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.81e-05	0.000644	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.47e-05	0.000585	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.36e-05	0.000568	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.34e-05	0.000563	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.29e-05	0.000556	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GCLC—chronic obstructive pulmonary disease	3.25e-05	0.000549	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.13e-05	0.000528	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.1e-05	0.000524	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.1e-05	0.000524	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL1B—chronic obstructive pulmonary disease	3.06e-05	0.000516	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	3.04e-05	0.000514	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CTGF—chronic obstructive pulmonary disease	2.97e-05	0.000501	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.88e-05	0.000487	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.88e-05	0.000486	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.83e-05	0.000478	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.73e-05	0.000462	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.67e-05	0.000451	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	2.6e-05	0.000439	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.43e-05	0.000411	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.42e-05	0.000408	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—chronic obstructive pulmonary disease	2.33e-05	0.000394	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.32e-05	0.000392	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.28e-05	0.000385	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.25e-05	0.000381	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.25e-05	0.00038	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.1e-05	0.000354	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.06e-05	0.000348	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.99e-05	0.000336	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.92e-05	0.000325	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.86e-05	0.000315	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6—chronic obstructive pulmonary disease	1.79e-05	0.000302	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.67e-05	0.000283	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.66e-05	0.000281	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.64e-05	0.000277	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.54e-05	0.000259	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.53e-05	0.000259	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.51e-05	0.000254	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.5e-05	0.000253	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.42e-05	0.00024	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.4e-05	0.000237	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.38e-05	0.000233	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALB—chronic obstructive pulmonary disease	1.35e-05	0.000228	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.31e-05	0.000221	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NOS3—chronic obstructive pulmonary disease	1.29e-05	0.000218	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.28e-05	0.000216	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.26e-05	0.000214	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.16e-05	0.000196	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.15e-05	0.000195	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.14e-05	0.000192	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.06e-05	0.000179	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1e-05	0.000169	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.84e-06	0.000166	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.7e-06	0.000164	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.04e-06	0.000153	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.57e-06	0.000145	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	6.82e-06	0.000115	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	6.52e-06	0.00011	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	5.83e-06	9.84e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	5.57e-06	9.42e-05	CbGpPWpGaD
